Scroll

corticotropin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
corticosteroids, except prednisolone derivatives	4931	9002-60-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: corticotropin ACTH corticotrophin adrenocorticotrophic hormone acthar gel cortrophin corticotropin zinc hydroxide corticotropin-zinc hydroxide cortrophin-zinc	A hormone made in the pituitary gland. ACTH acts on the outer part of the adrenal gland to control its release of corticosteroid hormones. More ACTH is made during times of stress. Molecular weight: 4541.14 Formula: C207H308N56O58S CLOGP: LIPINSKI: None HAC: 114 HDO: 63 TPSA: 1836.25 ALOGS: ROTB: 145

Molecule

Description

Molfile Inchi Smiles

Synonyms:

corticotropin
ACTH
corticotrophin
adrenocorticotrophic hormone
acthar gel
cortrophin
corticotropin zinc hydroxide
corticotropin-zinc hydroxide
cortrophin-zinc

A hormone made in the pituitary gland. ACTH acts on the outer part of the adrenal gland to control its release of corticosteroid hormones. More ACTH is made during times of stress.

Molecular weight: 4541.14
Formula: C207H308N56O58S
CLOGP:
LIPINSKI: None
HAC: 114
HDO: 63
TPSA: 1836.25
ALOGS:
ROTB: 145

Drug dosage:

Dose	Unit	Route
25	U	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
July 3, 1950	FDA	SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	164.63	19.77	88	6888	48390	63433656
Injection site bruising	136.44	19.77	74	6902	41836	63440210
Product dose omission issue	134.15	19.77	146	6830	234167	63247879
Blood glucose increased	75.45	19.77	67	6909	83689	63398357
Swelling face	65.72	19.77	55	6921	63420	63418626
Therapy cessation	65.18	19.77	41	6935	30416	63451630
Fluid retention	52.24	19.77	47	6929	59639	63422407
Weight increased	50.27	19.77	97	6879	260695	63221351
Epidural lipomatosis	43.35	19.77	8	6968	111	63481935
Skin hyperpigmentation	42.44	19.77	18	6958	5903	63476143
COVID-19	42.39	19.77	57	6919	113046	63369000
Magnetic resonance imaging head abnormal	40.19	19.77	13	6963	2000	63480046
Cushingoid	39.23	19.77	19	6957	8466	63473580
Infantile spasms	38.63	19.77	8	6968	207	63481839
Insomnia	37.75	19.77	77	6899	215175	63266871
Injection site discolouration	34.56	19.77	17	6959	7831	63474215
Feeling abnormal	32.03	19.77	58	6918	148334	63333712
Peripheral swelling	31.00	19.77	81	6895	265861	63216185
Illness	30.44	19.77	32	6944	49027	63433019
Irritability	27.79	19.77	25	6951	31669	63450377
Death	27.57	19.77	97	6879	374284	63107762
Polymyositis	25.49	19.77	9	6967	1807	63480239
Appetite disorder	23.99	19.77	13	6963	7308	63474738
Gait disturbance	23.62	19.77	58	6918	183120	63298926
Hospitalisation	23.31	19.77	37	6939	85044	63397002
Increased appetite	23.23	19.77	14	6962	9616	63472430
Nail pigmentation	22.36	19.77	5	6971	187	63481859
Visual impairment	20.79	19.77	35	6941	84411	63397635
Seizure	20.38	19.77	45	6931	132589	63349457
Mood altered	20.02	19.77	15	6961	14728	63467318
Condition aggravated	19.81	19.77	92	6884	402125	63079921
Surgery	19.77	19.77	22	6954	35890	63446156

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infantile spasms	68.52	26.77	12	2431	198	34954290
Fluid retention	60.79	26.77	32	2411	26855	34927633
Product dose omission issue	48.12	26.77	50	2393	119661	34834827
Hospitalisation	47.50	26.77	36	2407	56866	34897622
Blood glucose increased	42.45	26.77	36	2407	66682	34887806
Irritability	41.01	26.77	24	2419	24666	34929822
Weight increased	39.41	26.77	40	2403	92993	34861495
Drug ineffective	38.06	26.77	92	2351	456659	34497829
Insomnia	37.47	26.77	41	2402	103866	34850622
Multiple sclerosis relapse	36.55	26.77	18	2425	13115	34941373
Multiple-drug resistance	33.81	26.77	13	2430	5226	34949262
Intramyelinic oedema	31.51	26.77	4	2439	4	34954484
Magnetic resonance imaging head abnormal	27.57	26.77	8	2435	1353	34953135

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Injection site bruising	118.42	22.62	60	6264	40942	79697122
Product dose omission issue	106.88	22.62	114	6210	247423	79490641
Multiple sclerosis relapse	105.70	22.62	58	6266	46475	79691589
Blood glucose increased	80.05	22.62	69	6255	114906	79623158
Therapy cessation	72.24	22.62	42	6282	37520	79700544
Fluid retention	65.73	22.62	50	6274	69759	79668305
Insomnia	58.70	22.62	84	6240	245086	79492978
Cushingoid	56.30	22.62	23	6301	9529	79728535
Weight increased	53.58	22.62	86	6238	277300	79460764
Irritability	51.39	22.62	35	6289	41109	79696955
Swelling face	48.02	22.62	42	6282	71170	79666894
Infantile spasms	44.82	22.62	9	6315	279	79737785
Skin hyperpigmentation	37.70	22.62	16	6308	7287	79730777
Peripheral swelling	37.00	22.62	72	6252	269545	79468519
Magnetic resonance imaging head abnormal	36.43	22.62	12	6312	2714	79735350
Hypertension	34.52	22.62	79	6245	330913	79407151
Drug ineffective	30.63	22.62	167	6157	1080746	78657318
Intramyelinic oedema	30.53	22.62	4	6320	5	79738059
Feeling abnormal	28.83	22.62	48	6276	159151	79578913
Multiple-drug resistance	28.68	22.62	14	6310	8794	79729270
Epidural lipomatosis	27.37	22.62	8	6316	1220	79736844
Increased appetite	27.36	22.62	15	6309	11963	79726101
Death	23.59	22.62	98	6226	566416	79171648

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H01AA01	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES ACTH
FDA CS	M0000499	Adrenocorticotropic Hormone
CHEBI has role	CHEBI:33295	diagnostic aid
FDA EPC	N0000175941	Adrenocorticotropic Hormone

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
West syndrome	indication	28055006
Stevens-Johnson syndrome	indication	73442001	DOID:0050426
Exacerbation of multiple sclerosis	indication	192929006

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Stimulation of the adrenal cortex where there is a general deficiency of ACTH	Indication
Cattle	Stimulation of the adrenal cortex where there is a general deficiency of ACTH	Indication
Cattle	Primary bovine ketosis	Indication
Dogs	Diagnostic aid to test for adrenal dysfunction	Indication
Dogs	Stimulation of the adrenal cortex where there is a general deficiency of ACTH	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Adrenomone	Dechra, Ltd.	1
ACTH Gel	Bimeda Animal Health Limited	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.15	acidic
pKa2	3.37	acidic
pKa3	3.62	acidic
pKa4	3.86	acidic
pKa5	4.07	acidic
pKa6	4.31	acidic
pKa7	4.6	acidic
pKa8	9.43	acidic
pKa9	10.05	acidic
pKa10	12.25	acidic
pKa11	12.36	acidic
pKa12	12.63	acidic
pKa13	12.69	acidic
pKa14	12.93	acidic
pKa15	13.11	acidic
pKa16	13.11	acidic
pKa17	13.22	acidic
pKa18	13.41	acidic
pKa19	13.55	acidic
pKa20	13.6	acidic
pKa21	13.66	acidic
pKa22	13.75	acidic
pKa23	13.76	acidic
pKa24	13.79	acidic
pKa25	13.89	acidic
pKa26	14.0	acidic
pKa27	11.5	Basic
pKa28	11.26	Basic
pKa29	11.01	Basic
pKa30	10.81	Basic
pKa31	10.55	Basic
pKa32	10.3	Basic
pKa33	9.94	Basic
pKa34	7.62	Basic
pKa35	6.69	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Adrenocorticotropic hormone receptor	GPCR	Q01718	ACTHR_HUMAN	AGONIST			UNKNOWN	IUPHAR
Melanocortin receptor 4	GPCR	P32245	MC4R_HUMAN	AGONIST	Ki	6.16	IUPHAR
Melanocortin receptor 3	GPCR	P41968	MC3R_HUMAN	AGONIST	Ki	7.06	IUPHAR
Melanocyte-stimulating hormone receptor	GPCR	Q01726	MSHR_HUMAN	AGONIST	Ki	8.60	IUPHAR
Adrenocorticotropic hormone receptor	GPCR		ACTHR_MOUSE	AGONIST	Kd	9.80	IUPHAR

External reference:

ID	Source
D00146	KEGG_DRUG
4018523	VUID
N0000146845	NUI
12427-33-7	SECONDARY_CAS_RN
4018523	VANDF
4022410	VANDF
CHEBI:3892	CHEBI
CHEMBL1201610	ChEMBL_ID
9050-75-3	SECONDARY_CAS_RN
DB01285	DRUGBANK_ID
2584471	RXNORM
2492	MMSL
326050	MMSL
4506	MMSL
4507	MMSL
84	MMSL
d00604	MMSL
002113	NDDF
002114	NDDF
126187000	SNOMEDCT_US
40789008	SNOMEDCT_US
C0001655	UMLSCUI
CHEMBL1201609	ChEMBL_ID
1366	INN_ID
16132265	PUBCHEM_CID
471	INN_ID
3633	IUPHAR_LIGAND_ID
K0U68Q2TXA	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
1 Detoxification	HUMAN OTC DRUG LABEL	81	55146-011	LIQUID	30 [hp_C]	ORAL	unapproved homeopathic	9 sections
Purified Cortrophin Gel	HUMAN PRESCRIPTION DRUG LABEL	1	62559-860	INJECTION	80 [USPU]	INTRAMUSCULAR	NDA	15 sections
Purified Cortrophin Gel	HUMAN PRESCRIPTION DRUG LABEL	1	62559-860	INJECTION	80 [USPU]	INTRAMUSCULAR	NDA	15 sections
Purified Cortrophin Gel	HUMAN PRESCRIPTION DRUG LABEL	1	62559-860	INJECTION	80 [USPU]	INTRAMUSCULAR	NDA	15 sections
Acthar	HUMAN PRESCRIPTION DRUG LABEL	1	63004-8710	INJECTION	80 [USPU]	INTRAMUSCULAR	NDA	27 sections
Acthar	HUMAN PRESCRIPTION DRUG LABEL	1	63004-8710	INJECTION	80 [USPU]	INTRAMUSCULAR	NDA	27 sections
Acthar	HUMAN PRESCRIPTION DRUG LABEL	1	63004-8710	INJECTION	80 [USPU]	INTRAMUSCULAR	NDA	27 sections